 Casey Greene
Concepts (418)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 32 | 2025 | 680 | 5.450 |
Why?
| | Gene Expression Profiling | 24 | 2026 | 1782 | 3.960 |
Why?
| | Single-Cell Analysis | 10 | 2026 | 358 | 3.620 |
Why?
| | Software | 18 | 2026 | 690 | 2.980 |
Why?
| | Machine Learning | 18 | 2024 | 585 | 2.680 |
Why?
| | Genomics | 18 | 2025 | 834 | 2.550 |
Why?
| | Transcriptome | 21 | 2026 | 1045 | 2.550 |
Why?
| | Sequence Analysis, RNA | 9 | 2026 | 442 | 2.360 |
Why?
| | Algorithms | 18 | 2025 | 1837 | 2.130 |
Why?
| | Gene Regulatory Networks | 10 | 2024 | 318 | 2.130 |
Why?
| | Information Dissemination | 6 | 2020 | 223 | 2.110 |
Why?
| | Epistasis, Genetic | 6 | 2023 | 66 | 1.620 |
Why?
| | Data Mining | 5 | 2018 | 117 | 1.530 |
Why?
| | Neoplasms | 13 | 2026 | 2875 | 1.520 |
Why?
| | Pseudomonas aeruginosa | 7 | 2024 | 356 | 1.520 |
Why?
| | Biomedical Research | 5 | 2025 | 710 | 1.510 |
Why?
| | Ovarian Neoplasms | 9 | 2025 | 586 | 1.450 |
Why?
| | Viral Vaccines | 2 | 2023 | 107 | 1.410 |
Why?
| | Rare Diseases | 2 | 2023 | 113 | 1.290 |
Why?
| | Databases, Genetic | 13 | 2022 | 248 | 1.270 |
Why?
| | Gene Expression | 4 | 2023 | 1490 | 1.090 |
Why?
| | Research Personnel | 2 | 2020 | 186 | 1.040 |
Why?
| | Genome-Wide Association Study | 10 | 2021 | 1406 | 1.010 |
Why?
| | Humans | 106 | 2026 | 144759 | 0.920 |
Why?
| | Natural Language Processing | 2 | 2024 | 103 | 0.900 |
Why?
| | Peer Review, Research | 2 | 2022 | 36 | 0.870 |
Why?
| | Nonlinear Dynamics | 2 | 2023 | 95 | 0.860 |
Why?
| | Journalism | 1 | 2024 | 5 | 0.850 |
Why?
| | Direct-To-Consumer Screening and Testing | 1 | 2024 | 2 | 0.840 |
Why?
| | Artificial Intelligence | 4 | 2024 | 365 | 0.820 |
Why?
| | Breeding | 1 | 2024 | 63 | 0.820 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2023 | 35 | 0.790 |
Why?
| | Cell Nucleus | 1 | 2026 | 618 | 0.750 |
Why?
| | Cystadenocarcinoma, Serous | 4 | 2025 | 84 | 0.740 |
Why?
| | User-Computer Interface | 4 | 2023 | 164 | 0.720 |
Why?
| | Societies, Scientific | 1 | 2021 | 49 | 0.680 |
Why?
| | Genetic Testing | 1 | 2024 | 478 | 0.660 |
Why?
| | Neurofibromin 1 | 2 | 2019 | 26 | 0.660 |
Why?
| | Metadata | 1 | 2020 | 17 | 0.650 |
Why?
| | Data Compression | 1 | 2020 | 8 | 0.640 |
Why?
| | Guidelines as Topic | 1 | 2022 | 267 | 0.620 |
Why?
| | Genetic Association Studies | 3 | 2016 | 372 | 0.590 |
Why?
| | Computer Security | 1 | 2019 | 25 | 0.590 |
Why?
| | Computer Simulation | 7 | 2025 | 1025 | 0.590 |
Why?
| | Precision Medicine | 5 | 2024 | 457 | 0.580 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 170 | 0.570 |
Why?
| | Confidentiality | 1 | 2019 | 79 | 0.570 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 549 | 0.570 |
Why?
| | Language | 1 | 2022 | 321 | 0.570 |
Why?
| | Scholarly Communication | 1 | 2018 | 4 | 0.550 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 30 | 0.550 |
Why?
| | ras Proteins | 2 | 2019 | 150 | 0.550 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2025 | 682 | 0.540 |
Why?
| | Access to Information | 1 | 2018 | 48 | 0.530 |
Why?
| | Probability | 3 | 2024 | 310 | 0.530 |
Why?
| | Biomedical Technology | 1 | 2018 | 49 | 0.520 |
Why?
| | Disease | 3 | 2018 | 98 | 0.520 |
Why?
| | Glioblastoma | 2 | 2019 | 353 | 0.510 |
Why?
| | Gene Silencing | 2 | 2018 | 205 | 0.500 |
Why?
| | alpha-Synuclein | 1 | 2017 | 46 | 0.500 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.490 |
Why?
| | Models, Biological | 3 | 2020 | 1821 | 0.490 |
Why?
| | Parasites | 1 | 2017 | 44 | 0.490 |
Why?
| | Genome, Human | 6 | 2018 | 422 | 0.480 |
Why?
| | Models, Genetic | 5 | 2019 | 536 | 0.480 |
Why?
| | Systems Biology | 3 | 2018 | 72 | 0.470 |
Why?
| | Gene Ontology | 5 | 2020 | 53 | 0.470 |
Why?
| | MicroRNAs | 1 | 2022 | 701 | 0.460 |
Why?
| | Workflow | 1 | 2017 | 184 | 0.450 |
Why?
| | Quantitative Trait, Heritable | 1 | 2016 | 118 | 0.450 |
Why?
| | Research | 1 | 2018 | 431 | 0.450 |
Why?
| | Protein Interaction Maps | 1 | 2015 | 51 | 0.440 |
Why?
| | Unsupervised Machine Learning | 4 | 2024 | 22 | 0.440 |
Why?
| | Neurodegenerative Diseases | 1 | 2017 | 151 | 0.430 |
Why?
| | Bacterial Proteins | 2 | 2020 | 955 | 0.420 |
Why?
| | Authorship | 2 | 2024 | 49 | 0.410 |
Why?
| | Internet | 5 | 2023 | 699 | 0.400 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 732 | 0.400 |
Why?
| | Models, Theoretical | 1 | 2017 | 582 | 0.400 |
Why?
| | Bayes Theorem | 5 | 2018 | 433 | 0.390 |
Why?
| | RNA, Untranslated | 1 | 2014 | 124 | 0.370 |
Why?
| | Cluster Analysis | 3 | 2024 | 521 | 0.350 |
Why?
| | Drosophila melanogaster | 5 | 2019 | 236 | 0.340 |
Why?
| | Microbiota | 2 | 2017 | 781 | 0.340 |
Why?
| | Pandemics | 5 | 2023 | 1694 | 0.340 |
Why?
| | Bibliometrics | 2 | 2024 | 63 | 0.330 |
Why?
| | Signal Transduction | 8 | 2020 | 5226 | 0.330 |
Why?
| | Writing | 2 | 2024 | 100 | 0.330 |
Why?
| | Publishing | 2 | 2024 | 114 | 0.330 |
Why?
| | Embryonic Development | 3 | 2020 | 125 | 0.310 |
Why?
| | Databases, Factual | 2 | 2018 | 1486 | 0.300 |
Why?
| | Molecular Sequence Annotation | 5 | 2023 | 105 | 0.300 |
Why?
| | Animals | 20 | 2026 | 38058 | 0.300 |
Why?
| | Terminology as Topic | 3 | 2022 | 255 | 0.290 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2010 | 99 | 0.290 |
Why?
| | Scleroderma, Systemic | 3 | 2017 | 123 | 0.290 |
Why?
| | Supervised Machine Learning | 2 | 2020 | 23 | 0.280 |
Why?
| | Female | 24 | 2025 | 78271 | 0.280 |
Why?
| | Genome | 2 | 2019 | 306 | 0.280 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2145 | 0.260 |
Why?
| | Betacoronavirus | 2 | 2020 | 286 | 0.260 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 928 | 0.250 |
Why?
| | Drosophila Proteins | 2 | 2019 | 212 | 0.240 |
Why?
| | Homologous Recombination | 1 | 2025 | 36 | 0.230 |
Why?
| | Proteomics | 4 | 2021 | 1195 | 0.230 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 384 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 378 | 0.220 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 372 | 0.220 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 291 | 0.220 |
Why?
| | Publications | 2 | 2022 | 48 | 0.220 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3409 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2363 | 0.200 |
Why?
| | Sexism | 1 | 2024 | 70 | 0.200 |
Why?
| | Mice | 12 | 2025 | 18339 | 0.200 |
Why?
| | Science | 1 | 2024 | 56 | 0.190 |
Why?
| | Cystic Fibrosis | 2 | 2024 | 1158 | 0.190 |
Why?
| | Causality | 1 | 2023 | 126 | 0.190 |
Why?
| | Cell Line, Tumor | 4 | 2019 | 3540 | 0.190 |
Why?
| | Vaccines, Subunit | 1 | 2023 | 53 | 0.190 |
Why?
| | Breast Neoplasms | 2 | 2015 | 2452 | 0.190 |
Why?
| | Pedigree | 1 | 2024 | 514 | 0.190 |
Why?
| | Dogs | 1 | 2024 | 437 | 0.190 |
Why?
| | Sample Size | 1 | 2022 | 123 | 0.180 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2019 | 255 | 0.180 |
Why?
| | Mushroom Bodies | 2 | 2019 | 4 | 0.180 |
Why?
| | Hedgehog Proteins | 2 | 2021 | 197 | 0.180 |
Why?
| | Pseudomonas Infections | 1 | 2024 | 221 | 0.180 |
Why?
| | Male | 16 | 2025 | 72315 | 0.170 |
Why?
| | Periodicals as Topic | 1 | 2024 | 203 | 0.170 |
Why?
| | Quality Control | 1 | 2021 | 163 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Neoplasm Grading | 4 | 2025 | 307 | 0.170 |
Why?
| | Fibrosis | 2 | 2021 | 548 | 0.160 |
Why?
| | High-Throughput Screening Assays | 2 | 2014 | 175 | 0.160 |
Why?
| | Gamma Rays | 1 | 2021 | 56 | 0.160 |
Why?
| | Cooperative Behavior | 2 | 2021 | 465 | 0.160 |
Why?
| | Bone Development | 1 | 2021 | 52 | 0.160 |
Why?
| | Linear Models | 1 | 2023 | 854 | 0.160 |
Why?
| | Medical Informatics | 1 | 2021 | 97 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 77 | 0.160 |
Why?
| | Organ Specificity | 3 | 2017 | 312 | 0.160 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 18 | 0.160 |
Why?
| | Bone Diseases | 1 | 2021 | 61 | 0.160 |
Why?
| | Electronic Health Records | 3 | 2018 | 1173 | 0.160 |
Why?
| | Mutation | 5 | 2025 | 4089 | 0.160 |
Why?
| | Hemerythrin | 1 | 2020 | 2 | 0.160 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 919 | 0.160 |
Why?
| | Privacy | 1 | 2020 | 41 | 0.160 |
Why?
| | Histone Code | 1 | 2020 | 38 | 0.160 |
Why?
| | Alzheimer Disease | 2 | 2017 | 621 | 0.150 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.150 |
Why?
| | Systems Integration | 2 | 2017 | 36 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1455 | 0.150 |
Why?
| | Neurofibromatosis 1 | 1 | 2020 | 54 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2021 | 151 | 0.150 |
Why?
| | Phenotype | 4 | 2021 | 3162 | 0.150 |
Why?
| | Genetic Fitness | 1 | 2020 | 59 | 0.150 |
Why?
| | Base Sequence | 1 | 2022 | 2190 | 0.150 |
Why?
| | Exons | 1 | 2020 | 358 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 219 | 0.140 |
Why?
| | Cell Hypoxia | 1 | 2020 | 247 | 0.140 |
Why?
| | Biofilms | 2 | 2019 | 278 | 0.140 |
Why?
| | Cerebellar Neoplasms | 1 | 2021 | 177 | 0.140 |
Why?
| | Gene Expression Regulation | 3 | 2018 | 2608 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 2018 | 32 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 400 | 0.140 |
Why?
| | Medulloblastoma | 1 | 2021 | 215 | 0.140 |
Why?
| | Hypertension | 2 | 2019 | 1263 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 529 | 0.140 |
Why?
| | Pseudomonas fluorescens | 1 | 2018 | 2 | 0.140 |
Why?
| | Proteins | 2 | 2016 | 1021 | 0.140 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 345 | 0.140 |
Why?
| | DNA Repair | 2 | 2011 | 256 | 0.140 |
Why?
| | Sex Factors | 1 | 2024 | 2112 | 0.140 |
Why?
| | Atlases as Topic | 1 | 2018 | 11 | 0.140 |
Why?
| | Bone and Bones | 1 | 2021 | 314 | 0.140 |
Why?
| | Cyclic GMP | 1 | 2018 | 92 | 0.140 |
Why?
| | Recombinational DNA Repair | 1 | 2018 | 19 | 0.140 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1313 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2019 | 272 | 0.130 |
Why?
| | Alternative Splicing | 1 | 2020 | 247 | 0.130 |
Why?
| | Glomerulonephritis | 1 | 2018 | 45 | 0.130 |
Why?
| | Pennsylvania | 1 | 2018 | 138 | 0.130 |
Why?
| | Down Syndrome | 1 | 2025 | 534 | 0.130 |
Why?
| | Public Sector | 1 | 2017 | 17 | 0.130 |
Why?
| | False Positive Reactions | 1 | 2018 | 121 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 558 | 0.130 |
Why?
| | Starvation | 1 | 2017 | 23 | 0.130 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 173 | 0.130 |
Why?
| | Trans-Activators | 1 | 2020 | 405 | 0.130 |
Why?
| | Phosphoproteins | 1 | 2019 | 344 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 442 | 0.130 |
Why?
| | Drug Design | 1 | 2018 | 173 | 0.130 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 187 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 771 | 0.120 |
Why?
| | Data Collection | 1 | 2019 | 633 | 0.120 |
Why?
| | Information Storage and Retrieval | 1 | 2017 | 121 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 293 | 0.120 |
Why?
| | Multiple Myeloma | 1 | 2019 | 291 | 0.120 |
Why?
| | Genome, Microbial | 1 | 2016 | 7 | 0.120 |
Why?
| | Amygdala | 1 | 2017 | 198 | 0.120 |
Why?
| | Body Mass Index | 1 | 2025 | 2438 | 0.120 |
Why?
| | Microbial Consortia | 1 | 2016 | 20 | 0.120 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 15 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2018 | 758 | 0.120 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2018 | 327 | 0.120 |
Why?
| | Drug Repositioning | 1 | 2015 | 41 | 0.110 |
Why?
| | Blood Pressure | 2 | 2019 | 1769 | 0.110 |
Why?
| | Phylogeny | 1 | 2020 | 1016 | 0.110 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 510 | 0.110 |
Why?
| | Structure-Activity Relationship | 1 | 2016 | 570 | 0.110 |
Why?
| | Memory | 1 | 2017 | 295 | 0.110 |
Why?
| | Toxicology | 1 | 2015 | 49 | 0.110 |
Why?
| | Research Design | 1 | 2021 | 1135 | 0.110 |
Why?
| | Social Behavior | 1 | 2017 | 288 | 0.110 |
Why?
| | Search Engine | 1 | 2015 | 12 | 0.110 |
Why?
| | Knowledge Bases | 1 | 2015 | 28 | 0.110 |
Why?
| | RNA | 4 | 2024 | 940 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1166 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2015 | 172 | 0.100 |
Why?
| | Metabolome | 1 | 2017 | 384 | 0.100 |
Why?
| | Genes | 3 | 2013 | 226 | 0.100 |
Why?
| | Prognosis | 3 | 2021 | 4282 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2018 | 456 | 0.100 |
Why?
| | Hospital Mortality | 1 | 2018 | 1030 | 0.100 |
Why?
| | Biological Phenomena | 1 | 2013 | 4 | 0.100 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2015 | 266 | 0.100 |
Why?
| | Macrophages | 1 | 2021 | 1511 | 0.100 |
Why?
| | Circadian Rhythm | 1 | 2017 | 514 | 0.100 |
Why?
| | Proteome | 1 | 2017 | 518 | 0.090 |
Why?
| | Sequence Analysis, DNA | 3 | 2025 | 824 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1720 | 0.090 |
Why?
| | Podocytes | 1 | 2013 | 80 | 0.090 |
Why?
| | Length of Stay | 1 | 2018 | 1337 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1985 | 0.090 |
Why?
| | Intensive Care Units | 1 | 2018 | 916 | 0.090 |
Why?
| | Adult | 8 | 2025 | 40449 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 612 | 0.090 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 457 | 0.090 |
Why?
| | Brain | 1 | 2024 | 2933 | 0.090 |
Why?
| | Middle Aged | 10 | 2025 | 35875 | 0.090 |
Why?
| | Cell Lineage | 1 | 2013 | 376 | 0.090 |
Why?
| | Survival Analysis | 1 | 2015 | 1382 | 0.090 |
Why?
| | Cell Line | 2 | 2017 | 2882 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 3077 | 0.080 |
Why?
| | Child | 5 | 2026 | 22633 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2018 | 947 | 0.080 |
Why?
| | Bias | 1 | 2012 | 202 | 0.080 |
Why?
| | Aged | 8 | 2025 | 25913 | 0.080 |
Why?
| | Pediatrics | 1 | 2019 | 1114 | 0.080 |
Why?
| | Decision Making | 1 | 2018 | 975 | 0.080 |
Why?
| | Knowledge | 1 | 2010 | 57 | 0.080 |
Why?
| | Multifactor Dimensionality Reduction | 1 | 2010 | 2 | 0.080 |
Why?
| | Microglia | 2 | 2024 | 268 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1318 | 0.080 |
Why?
| | Models, Statistical | 3 | 2020 | 681 | 0.080 |
Why?
| | Memory, Long-Term | 2 | 2019 | 12 | 0.080 |
Why?
| | Transcription Factors | 1 | 2017 | 1741 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2013 | 427 | 0.070 |
Why?
| | Rats | 3 | 2013 | 5597 | 0.070 |
Why?
| | Biopsy | 3 | 2018 | 1075 | 0.070 |
Why?
| | Geography | 1 | 2009 | 203 | 0.070 |
Why?
| | Parkinson Disease | 1 | 2015 | 600 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1414 | 0.070 |
Why?
| | Gene Frequency | 1 | 2009 | 481 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2015 | 4154 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 6048 | 0.060 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 653 | 0.060 |
Why?
| | Multifactorial Inheritance | 1 | 2008 | 202 | 0.060 |
Why?
| | United States | 2 | 2021 | 15966 | 0.060 |
Why?
| | Terminal Repeat Sequences | 1 | 2006 | 17 | 0.060 |
Why?
| | Cytokines | 2 | 2018 | 2061 | 0.060 |
Why?
| | Alleles | 1 | 2009 | 879 | 0.060 |
Why?
| | Retroelements | 1 | 2006 | 51 | 0.060 |
Why?
| | Bone Density | 2 | 2021 | 482 | 0.060 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2025 | 39 | 0.050 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2025 | 42 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2009 | 3604 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2019 | 11679 | 0.050 |
Why?
| | Pilot Projects | 2 | 2022 | 1886 | 0.050 |
Why?
| | Europe | 1 | 2025 | 412 | 0.050 |
Why?
| | Culture Media | 1 | 2024 | 161 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 102 | 0.050 |
Why?
| | Microarray Analysis | 1 | 2023 | 117 | 0.050 |
Why?
| | Metals | 1 | 2024 | 142 | 0.050 |
Why?
| | Smoking | 1 | 2010 | 1472 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 558 | 0.050 |
Why?
| | Astrocytes | 1 | 2024 | 222 | 0.050 |
Why?
| | Sputum | 1 | 2024 | 308 | 0.040 |
Why?
| | Budgets | 1 | 2021 | 14 | 0.040 |
Why?
| | Interdisciplinary Research | 1 | 2021 | 26 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5992 | 0.040 |
Why?
| | Gene Library | 1 | 2021 | 126 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 872 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 45 | 0.040 |
Why?
| | Neurofibroma | 1 | 2020 | 5 | 0.040 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2020 | 13 | 0.040 |
Why?
| | Neurofibroma, Plexiform | 1 | 2020 | 12 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 331 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2021 | 211 | 0.040 |
Why?
| | Osteoblasts | 1 | 2021 | 145 | 0.040 |
Why?
| | Antigens, CD20 | 1 | 2019 | 35 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 102 | 0.040 |
Why?
| | Data Accuracy | 1 | 2020 | 65 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 93 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2021 | 510 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 72 | 0.040 |
Why?
| | Manuscripts, Medical as Topic | 1 | 2019 | 5 | 0.040 |
Why?
| | Candida albicans | 1 | 2019 | 61 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 139 | 0.040 |
Why?
| | Genome, Fungal | 1 | 2019 | 42 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 462 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2025 | 8265 | 0.040 |
Why?
| | Reward | 1 | 2021 | 247 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 919 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2019 | 76 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 154 | 0.040 |
Why?
| | Young Adult | 3 | 2021 | 14105 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 64 | 0.040 |
Why?
| | Osteogenesis | 1 | 2021 | 208 | 0.040 |
Why?
| | Locomotion | 1 | 2019 | 105 | 0.040 |
Why?
| | Wilms Tumor | 1 | 2019 | 85 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 374 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 327 | 0.030 |
Why?
| | Genome, Bacterial | 1 | 2019 | 155 | 0.030 |
Why?
| | Mentoring | 1 | 2021 | 166 | 0.030 |
Why?
| | Sarcoma, Ewing | 1 | 2019 | 102 | 0.030 |
Why?
| | Genes, Neoplasm | 1 | 2018 | 25 | 0.030 |
Why?
| | Two-Hybrid System Techniques | 1 | 2018 | 59 | 0.030 |
Why?
| | Pentose Phosphate Pathway | 1 | 2018 | 55 | 0.030 |
Why?
| | Neuroblastoma | 1 | 2019 | 174 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 52 | 0.030 |
Why?
| | Monocytes | 1 | 2021 | 538 | 0.030 |
Why?
| | Bacteria | 1 | 2025 | 889 | 0.030 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2018 | 24 | 0.030 |
Why?
| | Nephrotic Syndrome | 1 | 2018 | 44 | 0.030 |
Why?
| | Acid Phosphatase | 1 | 2017 | 14 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2019 | 310 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 196 | 0.030 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 128 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2018 | 117 | 0.030 |
Why?
| | Mouth | 1 | 2017 | 88 | 0.030 |
Why?
| | Isoenzymes | 1 | 2018 | 299 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 477 | 0.030 |
Why?
| | GTPase-Activating Proteins | 1 | 2017 | 82 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2017 | 96 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2018 | 133 | 0.030 |
Why?
| | Patient Care Planning | 1 | 2018 | 169 | 0.030 |
Why?
| | Motivation | 1 | 2021 | 610 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 462 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 117 | 0.030 |
Why?
| | Chromatin | 1 | 2021 | 561 | 0.030 |
Why?
| | Databases, Protein | 1 | 2016 | 90 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1135 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 965 | 0.030 |
Why?
| | Genetic Loci | 1 | 2017 | 261 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1257 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2016 | 68 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 85 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2089 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2018 | 380 | 0.030 |
Why?
| | Saliva | 1 | 2017 | 249 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 750 | 0.030 |
Why?
| | Blood Proteins | 1 | 2017 | 249 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 321 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2021 | 748 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2018 | 239 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2017 | 304 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 479 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1519 | 0.030 |
Why?
| | DNA Damage | 1 | 2018 | 430 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2117 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 836 | 0.030 |
Why?
| | Esophagus | 1 | 2017 | 261 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 917 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 10779 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1053 | 0.030 |
Why?
| | Oxygen | 1 | 2020 | 995 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1496 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 573 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2016 | 610 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 905 | 0.030 |
Why?
| | Heart Rate | 1 | 2017 | 855 | 0.020 |
Why?
| | Colorado | 1 | 2024 | 4564 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 688 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2021 | 2496 | 0.020 |
Why?
| | Regression Analysis | 1 | 2015 | 1003 | 0.020 |
Why?
| | Aging | 1 | 2024 | 1966 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 969 | 0.020 |
Why?
| | Support Vector Machine | 1 | 2013 | 36 | 0.020 |
Why?
| | Organogenesis | 1 | 2013 | 65 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2947 | 0.020 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 173 | 0.020 |
Why?
| | Nanotechnology | 1 | 2013 | 126 | 0.020 |
Why?
| | Apoptosis | 1 | 2021 | 2430 | 0.020 |
Why?
| | Risk | 1 | 2015 | 911 | 0.020 |
Why?
| | Computer Graphics | 1 | 2012 | 41 | 0.020 |
Why?
| | Skin | 1 | 2017 | 755 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 398 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 22428 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 553 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 983 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2832 | 0.020 |
Why?
| | Caenorhabditis elegans | 1 | 2013 | 337 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5868 | 0.020 |
Why?
| | Zebrafish Proteins | 1 | 2012 | 311 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4557 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 437 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 528 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 974 | 0.020 |
Why?
| | Curriculum | 1 | 2015 | 1059 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7173 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11787 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2013 | 2050 | 0.010 |
Why?
| | Lung | 1 | 2017 | 4109 | 0.010 |
Why?
| | Inflammation | 1 | 2015 | 2878 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2637 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 17066 | 0.010 |
Why?
|
|
Greene's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|